December Featured Cancer Clinical Trials

TOG 1314
Disease: Brain
Objective: The primary objective is to identify the highest, safe and well tolerated dose of Toca 511 administered intravenously to subjects with rHGG undergoing planned resection ≥ 80%.

OSU 1113
Disease: Breast
Objective: The primary objective is to assess the anti-tumor activity associated with trametinib monotherapy in patients with triple negative breast cancer (TNBC).

SWOG 1222
Disease: Breast
Objective: The primary objective is to test the benefit of interfering with the function of the estrogen receptor (ER) and providing downstream target inhibition (PI3K/AKT/mTOR) with a combination of optimal dose fulvestrant and everolimus (Arm 2) to improve progression-free survival compared to the optimal dose fulvestrant alone (Arm 1).

MLNM 1A13
Disease: Amyloidosis
Objective: The primary objective is to determine whether dexamethasone plus MLN9708 improves hematologic response (PR + VGPR + CR) versus a physician’s choice of a chemotherapy regimen as selected from the list of offered treatment options in patients diagnosed with relapsed or refractory AL amyloidosis.

NIH 1Z14
Disease: Graft vs. Host Disease
Objective: The primary objective is to develop and validate the Chronic GVHD-Activity Index (CGVHD-AI) as a measure of treatment response. This measure is intended to capture impairments caused by chronic GVHD. We expect that change in the CGVHD-AI could be used to measure treatment response because it will correlate with clinically significant changes reported by physicians and patients. The CGVHD-AI would be most appropriate for use in clinical trials where the goal is symptom relief and decreased disease activity.